This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Flucytosine

Authoring team

Flucytosine has attained approval as an adjunct antifungal agent in treating systemic Candida spp. or Cryptococcus spp. infections.

Off-label, flucytosine is utilized in treating paediatric endocarditis caused by Aspergillus spp. (1)

Cautions: (2)

  • blood disorders
  • renal and hepatic impairment
  • liver function tests and a full blood count are required
  • pregnancy and breast feeding

Side-effects:

  • rashes
  • nausea and vomiting
  • diarrhoea
  • leucopenia
  • thrombocytopenia

Routes of administration;

  • Oral; Tablets
  • IV infusion

References

  1. McKeny T et al. Antifungal Antibiotics. Treasure Island (FL): StatPearls Publishing. 2025 Jan.
  2. British National Formulary (BNF); NICE Evidence Services (UK access only)

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.